Happify Health and Almirall Go Live with Digital Solution to Support Psoriasis Patients
-
Happify Health and Almirall’s partnership kicks off with the launch of Claro, a digital wellness solution for people with psoriasis to help improve their mental wellbeing, inSpain , theU.K. andItaly . -
An estimated
20% to30% of patients with moderate to severe psoriasis also suffer from mental health issues, like anxiety and depression1. -
Claro is the first iteration of
Happify Health's platform for people with psoriasis. It is available in English, Spanish, Italian and French.
Psoriasis is one of the world's most prevalent skin diseases, affecting about 60 million people worldwide2. A 2019 study in Maedica, a
“At Almirall, we are proud to offer psoriasis patients a wide range of medicines that cover the whole spectrum of the disease, from mild to severe. Claro helps us to fulfill our commitment to people living with psoriasis, providing them with an enhanced solution addressed to their wellbeing, so they can get their lives back,” said Dr.
“Psoriasis is a significant burden in the daily life of
About Almirall
Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients' world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.
The company, founded in 1943 and headquartered in
For more information, please visit www.almirall.com
About
Our global platform is available in 10 languages, supports more than 10 chronic conditions, and covers more than 20 million lives.
References
-
H.L. Richards ,D.G. Fortune ,C.E. Griffiths , C.J. Main. The contribution of perceptions of stigmatization to disability in patients with psoriasis. J Psychosom Res., 50 (2001), pp. 11-15. -
National Psoriasis Foundation 2008 Survey Snapshot. Available from: PTT-24087-quality-of-life-issues-and-measurement-in-patients-with-psor (researchgate.net) -
E.A. Dowlatshahi , M. Wakkee,L.R. Arends ,T. Nijsten . The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: A systematic review and meta-analysis. J Invest Dermatol., 134 (2014), pp. 1542-1551. -
M. Esposito ,R. Saraceno , A. Giunta,M. Maccarone ,S. Chimenti . An Italian study on psoriasis and depression. Dermatology., 212 (2006), pp. 123-127.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005204/en/
Happify Health Press Contact:
erin@cogentacom.com
(678) 294-2258
Mar Ramírez
Mar.ramirez@almirall.com
659 614 173
Source: